REG-4basebio Plc: Director/PDMR Shareholding

4BasebioAnnouncement

16/06/2022 15:30

16 June 2022

4basebio plc
(the "Company")
 

Director’s Dealings

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces that it was today notified that, on 16 June 2022,
David Roth, chief financial officer, acquired 5,000 ordinary shares at a price
of 430 pence per share.

As a result of the acquisition of ordinary shares, David Roth’s beneficial
holding comprises 317,000 ordinary shares representing approximately 2.6 per
cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

For further enquiries, please contact:

 4basebio plc                                        +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                   
                                                                         
 Cairn Financial Advisers LLP (Nominated Adviser )   +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                              
                                                                         
 finnCap Ltd (Broker)                                +44 (0)20 7220 0500 
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe                         
                                                                         

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1. Details of the person discharging managerial responsibilities/person
closely associated
1. Name                                     
David Roth
1. Reason for notification
1. Position/Status                     
Chief Financial Officer
1. Initial notification/ Amendment          Initial
1. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
1. Name                                   
   4basebio plc
1. LEI
                                       
  213800E2DX9EAIUNCB30
1. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
1. Description of the financial instrument, type Ordinary Shares of instrument

 Identification Code                       ISIN:
GB00BMCLYF79
  
2. Nature of the transaction               Acquisition of
ordinary shares
  
3. Price(s) and volume(s)               Volume(s)
              Price (p)
  
5,000430p
1. Aggregated information  
  
- Aggregated Volume 5,000
- Price430 pence per share

 
1. Date of the transaction               16/06/2022
  
2. Place of the transaction London Stock Exchange, AIM


Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved